Nosa Plugs AB (“Nosa Plugs” or the “Company”) announced on June 11, 2025, that it has successfully completed an in vivo study of its intranasal drug delivery platform, Drug Delivery. The study demonstrated that a significant level of drug is absorbed into blood plasma when using the Drug Delivery system, confirming that the technology is effective and capable of achieving therapeutic concentrations. This milestone represents the final step in the Company’s proof of concept. The next anticipated phase is to secure a partnership with a pharmaceutical company for this delivery method.

In summary, we view the study results as an additional validation of Nosa Plugs’ drug delivery platform. The promising data is expected to drive renewed interest from pharmaceutical companies, with partnership talks already underway. The next key step for the Drug Delivery program is to finalize a partnership with a pharmaceutical company, targeted for completion in 2025, alongside continued testing and R&D to support the platform’s future development.

Read Analyst Group’s comment and an interview with Nosa Plugs CEO Adrian Liljefors here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group

This is a press release from Analyst Group regarding the publication of a comment on Nosa Plugs. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Läs mer på Analyst Group